Rituxan (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately- to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Rituxan is not recommended for treatment of patients with severe active infections.
Rituxan administration can result in serious, including fatal, adverse reactions. These include:
Rituxan administration can also result in additional serious, including fatal, adverse reactions including:
Patients should be closely observed for signs of infection if biologic agents and /or DMARDs other than methotrexate are used concomitantly.
Common adverse reactions include infusion reactions and infections.
For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.
Attention Healthcare Provider: Provide Medication Guide to patient prior to Rituxan infusion.